CHANGCHUN, China, Nov. 10 /Xinhua-PRNewswire/ -- Global Pharmatech, Inc. (OTC:GBLP) (BULLETIN BOARD: GBLP) a company that develops, manufactures and markets proprietary botanical drugs and dietary supplements, today announced that the State Intellectual Property Office of the P. R. China has recently granted a new innovation patent to one of its botanical drug candidates, XNYDT (Xianniuyaoditong) granule (patent number: ZL200310109939.3) to Natural Pharmatech (Jilin), a wholly owned subsidiary of Global Pharmatech, Inc. (Logo: http://211.154.41.99:9080/xprn/sa/200611101343.JPG ) The drug was developed according to previous clinical experience of traditional Chinese medicine. XNYDT granule is potentially indicated for the treatment of lumbosacral pain. Investigational New Drug (IND) application of XNYDT was approved by the SFDA, Chinese regulatory authority on June 1, 2005. Global Pharmatech is ready to start clinical development of this product. XNYDT is a botanical drug product, which is formulated using modern pharmaceutical technologies. Estimated cost of producing XNYDT is relatively lower than other traditional herbal products for the treatment of lumbosacral pain. Based on the data obtained from preliminary tests and previous clinical experiences of traditional Chinese medicine, this product is expected to have reasonable safety profile and to be more efficacies in comparison to other botanical products for the same indication on Chinese market. Lumbosacral pain is one of common chronic clinical problems in China. It could be induced by various causes. Dr. Xiaobo Sun, President and CEO of Global Pharmatech indicated: 'We are very glad to have a new drug candidate on our pipeline. This product will bring our company into a new therapeutic area. We believe that we will complete our clinical program of XNYDT for the SFDA market approval within the next three to four years.' About Global Pharmatech Global Pharmatech, through its subsidiaries, develops, manufactures and markets proprietary drugs that are based on Traditional Chinese Medicine using modern facilities and advanced R&D technologies. The company offers a full range of start-to-finish biotech services, from research and testing to manufacture and sale of liquid and solid dose products. The Company employs unique proprietary extraction methods and also licenses patents and technologies for botanical/biological drug products. Global Pharmatech's operations are currently based in the People's Republic of China with sales distribution centers in China, Malaysia, Singapore and Indonesia. For more information, please visit Global Pharmatech.com Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995 This news release contains forward-looking statements within the meaning of the 'safe harbour' provisions of the Private Securities Litigation Reform Act of 1995. These statements are based upon our current expectations and speak only as of the date hereof. Our actual results may differ materially and adversely from those expressed in any forward-looking statements as a result of various factors and uncertainties, including our ability to successfully develop and commercialize products, competitive products in our key markets, changes in consumer demand for our products, legislative, regulatory and competitive developments and general economic conditions. Our SEC filings discuss some of the important risk factors that may affect our business, results of operations and financial condition. We undertake no obligation to revise or update publicly any forward-looking statements for any reason. For more information, please contact: Zhuojun Li Investor Relations Global Pharmatech, Inc. Tel: +1-905-787-8225 Email: DATASOURCE: Global Pharmatech, Inc. CONTACT: Zhuojun Li, Investor Relations of Global Pharmatech, Inc., +1-905-787-8225 or Web Site: http://www.pharmatech.com/

Copyright